BR0308856A - Piranon e pirandion inibidores do rna polimerase dependente do rna do vìrus da hepatite c - Google Patents

Piranon e pirandion inibidores do rna polimerase dependente do rna do vìrus da hepatite c

Info

Publication number
BR0308856A
BR0308856A BR0308856-1A BR0308856A BR0308856A BR 0308856 A BR0308856 A BR 0308856A BR 0308856 A BR0308856 A BR 0308856A BR 0308856 A BR0308856 A BR 0308856A
Authority
BR
Brazil
Prior art keywords
hepatitis
inhibitors
piranon
pirandion
virus
Prior art date
Application number
BR0308856-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Allen J Borchardt
Michael Paul Goble
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR0308856A publication Critical patent/BR0308856A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
BR0308856-1A 2002-04-01 2003-03-21 Piranon e pirandion inibidores do rna polimerase dependente do rna do vìrus da hepatite c BR0308856A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36938102P 2002-04-01 2002-04-01
PCT/IB2003/001206 WO2003082848A1 (en) 2002-04-01 2003-03-21 Pyranon and pyrandion inhibitors of hepatitis c virus rna-dependent rna polymerase

Publications (1)

Publication Number Publication Date
BR0308856A true BR0308856A (pt) 2005-02-22

Family

ID=28675577

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308856-1A BR0308856A (pt) 2002-04-01 2003-03-21 Piranon e pirandion inibidores do rna polimerase dependente do rna do vìrus da hepatite c

Country Status (11)

Country Link
US (1) US6878727B2 (enExample)
EP (1) EP1490350B1 (enExample)
JP (1) JP2005526102A (enExample)
AT (1) ATE337309T1 (enExample)
AU (1) AU2003215826A1 (enExample)
BR (1) BR0308856A (enExample)
CA (1) CA2480583C (enExample)
DE (1) DE60307804T2 (enExample)
ES (1) ES2268394T3 (enExample)
MX (1) MXPA04009672A (enExample)
WO (1) WO2003082848A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2003000641A (es) * 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
US7148226B2 (en) * 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
IN2012DN04853A (enExample) 2004-02-20 2015-09-25 Boehringer Ingelheim Int
US7115749B2 (en) 2004-10-29 2006-10-03 Schering Corporation Substituted 5-oxo pyrazoles and [1,2,4]triazoles as antiviral agents
EP1881828A4 (en) * 2005-05-20 2009-06-03 Valeant Res & Dev TREATMENT OF HEPATITIS C (HCV) USING SUB-THERAPEUTIC DOSES OF RIBAVIRIN
US7816348B2 (en) * 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2008047694A1 (fr) * 2006-10-13 2008-04-24 Aska Pharmaceutical Co., Ltd. Procédé de fabrication d'un composé benzothiazole
EP2494991A1 (en) 2007-05-04 2012-09-05 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection
CA2693495A1 (en) * 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP2188274A4 (en) * 2007-08-03 2011-05-25 Boehringer Ingelheim Int VIRAL POLYMERASE HEMMER
EA201000948A1 (ru) 2007-12-19 2011-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы вирусной полимеразы

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1140049A (en) * 1977-12-22 1983-01-25 Dke J.E. Helgstran Pharmaceutical preparations from derivatives of hydroxycarbonylphosphonic acid
US6174868B1 (en) * 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US5846964A (en) * 1993-07-19 1998-12-08 Tokyo Tanabe Company Limited Hepatitis C virus proliferation inhibitor
IL129871A (en) * 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
AU777040B2 (en) * 1999-02-22 2004-09-30 Shire Biochem Inc. (1,8) naphthyridine derivatives having antiviral activity
AR034127A1 (es) * 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento

Also Published As

Publication number Publication date
CA2480583A1 (en) 2003-10-09
EP1490350A1 (en) 2004-12-29
AU2003215826A1 (en) 2003-10-13
WO2003082848A1 (en) 2003-10-09
ES2268394T3 (es) 2007-03-16
MXPA04009672A (es) 2004-11-12
DE60307804D1 (de) 2006-10-05
ATE337309T1 (de) 2006-09-15
US6878727B2 (en) 2005-04-12
CA2480583C (en) 2008-07-15
JP2005526102A (ja) 2005-09-02
EP1490350B1 (en) 2006-08-23
DE60307804T2 (de) 2007-01-18
US20030195239A1 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
DOP2003000641A (es) Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
EA200501689A1 (ru) Соединения в качестве ингибиторов вируса гепатита c
DE60319820D1 (de) Pyrazoloä1,5-aüpyrimidin-verbindungen als antivirale agentien
NO20070194L (no) Fremgangsmater for behandling av hepatitt C
CY1111480T1 (el) Αναστολεις πολυμερασης toy rna που εξαρταται απο to rna του ιου ηπατιτιδας c και συνθεσεις και θεραπευτικες αγωγες χρησιμοποιωντας αυτους
NO20045247L (no) Nukleosidderivater for behandling av hepatitt C-virusinfeksjon
BRPI0514176A (pt) inibidores de replicação de hcv
DK2251015T3 (da) Modificerede nukleotider til behandling af virusinfektioner og abnorm celleproliferation
NO20062428L (no) Kombinasjoner for HCV-behandling
NO20062146L (no) Nukleosidforbindelser for behandling av virusinfeksjoner
EA200500584A1 (ru) Нуклеозидные производные для лечения инфекционных заболеваний, вызванных вирусом гепатита c
DE60217465D1 (de) Nukleosidderivate als inhibitoren von rna-abhängiger rna viralpolymerase
BR0308856A (pt) Piranon e pirandion inibidores do rna polimerase dependente do rna do vìrus da hepatite c
NL1025544A1 (nl) Remmers van rna-afhankelijk rna-polymerase van hepatitis-c-virus en preparaten en behandelingen waarbij ze worden gebruikt.
CY1110437T1 (el) Χρηση παραγωγων καστανοσπερμινης για την θεραπεια της ηπατιτιδας c
NO20073632L (no) Behandling av hepatitt C med interferon-beta i en asiatisk populasjon
AU2003287216A8 (en) Gb virus c and methods of treating viral infections
TW200614989A (en) Inhibitors of HCV replication
CY1113987T1 (el) Τροποποιημενα νουκλεοσιδια για τη θεραπεια ιικων μολυνσεων και του μη κανονικου κυτταρικου πολλαπλασιασμου

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010.